World Health Organization Issues Warning Over Critical Shortage of Obesity Jabs
Under a tenth of patients that would benefit from GLP-1 drugs such as Wegovy can access them, caution the WHO as it publishes its first guidance on the medications.
With more than one billion individuals worldwide currently obese, it is urging broader and more equitable availability to these injectable treatments.
Per forecasts, more than two billion are projected to be obese by 2030 without intervention.
"Our latest guidelines recognises that obesity is a long-term condition that can be treated with holistic and continuous care," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are major hurdles to universal access to the treatments that can help people shift significant body mass, explains the body.
Weight-Loss Drug Supply Crisis
Even in the current best projected scenario, the production of such drugs might only reach about 100 million people – fewer than 10% of eligible patients, according to the WHO.
The guideline calls on governments and firms to widen access, through approaches including voluntary licensing.
The intellectual property rights on a key compound – the main ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026.
The Way Obesity Drugs Operate
The injections imitate a biological compound to delay gastric emptying, curb appetite and increase feelings of fullness so people consume fewer calories.
Individuals typically begin shedding pounds in the initial weeks of commencing the once-weekly jabs.
Studies suggests users may see weight return within a year of halting the medication, as their typical appetite return.
Being above a healthy weight increases your chance for experiencing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight concerns individuals in countries worldwide and was linked to millions of deaths worldwide in 2024, per the WHO.
